While fecal microbiota transplantation (FMT) is viewed as a relatively inexpensive and safe method for treating recurring Clostridium difficile infection and other maladies in humans, FMT is not without its challenges, particularly with regard to the screening and selection of fecal donors. In a recent Gut Microbes publication, Woodworth et al. discussed current challenges pertaining to FMT for human use1. The authors evaluate current recommendations for selection and screening of fecal donors as well as additional factors that may impact future donor screening recommendations.
Screening Donors for Fecal Microbiota Transplantation
Mitigating harm to recipients remains the primary driver of current exclusion criteria for donors. Woodworth et al. effectively summarize and present these exclusion criteria within Table 1 of their review1. Included within this table is a list of pathogens that have been screened for using either blood- or stool-based tests.It is noteworthy that the detection of viruses and parasites are among the most common reasons for donor exclusion based on stool testing2,3.
In addition, FMT donors/materials were screened for the following:
- Non-bacterial members of the gut microbiota
- Obesity and metabolic diseases
- Microbiome diversity
- Oncogenic potential of donor microbiota
- Antibiotic resistance
- Asymptomatic transmissible conditions
